Antiplatelets before or during endovascular therapy after intravenous thrombolysis for atherothrombotic large vessel

Satoshi Miyamoto1, Mikito Hayakawa2, Wataro Tsuruta1

  • 1Department of Endovascular Neurosurgery, Toranomon Hospital, Tokyo, Japan.

Re-occlusion and intravascular thrombus formation following mechanical thrombectomy (MT) in stroke patients worsen clinical outcomes. Although early administration of antiplatelet therapy (APT) prevents these complications, current guidelines advise against using APT soon after intravenous thrombolysis (IVT), making the management of atherothrombotic large vessel occlusion (AT-LVO) difficult. We investigated the safety of early APT for acute AT-LVO treated with MT following IVT. This post-hoc analysis of a registry study of 770 AT-LVO patients treated with MT across 51 institutions in Japan from January 2017 to December 2019, specifically targeted patients with anterior circulation AT-LVO. Safety endpoints were symptomatic intracranial hemorrhage (sICH), any intracranial hemorrhage (ICH), all hemorrhagic events and mortality at 90 days. The endpoints between patients in whom APT was initiated before or during MT (pre-/intra-MT APT group) and those with APT initiation after MT or treated without APT (post-MT/no APT group) were compared before and after propensity score-matching. Of the 164 patients included in the study (120 males, age 72 ± 11 years), 84 and 80 patients were included in each group. In the propensity score-matched cohort (37 patients each), the rate of all hemorrhagic events (14 vs. 22 %, p = 0.359), any ICH (8 vs. 14 %, p = 0.711), sICH (3 vs. 8 %, p = 0.615), and mortality (3 vs. 3 %, p = 1.000) did not differ significantly between the two groups. Early APT following IVT in acute AT-LVO treated with MT might be safe.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
467
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
608